C4 Therapeutics (CCCC) Price/OCF Ratio: History & Chart

C4 Therapeutics, Inc.(CCCC)

Biotechnology · Watertown, MA

$2.93-0.07 (-2.17%)

Delayed quote: Oct 6, 2026, 11:10 AM EDT

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.

Watertown, MA

104 employees

www.c4therapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Andrew J. Hirsch

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
C4 Therapeutics, Inc. (CCCC)	$323.41M	N/A	N/A	N/A	N/A
CapsoVision, Inc. (CV)vs ›	$326.20M	N/A	N/A	N/A	N/A
ClearPoint Neuro, Inc. (CLPT)vs ›	$330.79M	N/A	N/A	N/A	N/A
Cabaletta Bio, Inc. (CABA)vs ›	$330.92M	N/A	N/A	N/A	N/A
Mobia Medical, Inc. Common Stock (MOBI)vs ›	$310.71M	N/A	N/A	N/A	N/A
Agenus Inc. (AGEN)vs ›	$337.51M	N/A	418.54	418.54	418.54
Benitec Biopharma Inc. (BNTC)vs ›	$307.13M	N/A	N/A	N/A	N/A
Artiva Biotherapeutics, Inc. (ARTV)vs ›	$346.15M	N/A	N/A	N/A	N/A
Enanta Pharmaceuticals, Inc. (ENTA)vs ›	$357.37M	N/A	46.02	35.66	31.75
BridgeBio Oncology Therapeutics Inc. (BBOT)vs ›	$292.79M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

C4 Therapeutics, Inc. (CCCC)

$323.41M

N/A

CapsoVision, Inc. (CV)vs ›

$326.20M

N/A

ClearPoint Neuro, Inc. (CLPT)vs ›

$330.79M

N/A

Cabaletta Bio, Inc. (CABA)vs ›

$330.92M

N/A

Mobia Medical, Inc. Common Stock (MOBI)vs ›

$310.71M

N/A

Agenus Inc. (AGEN)vs ›

$337.51M

N/A

418.54

Benitec Biopharma Inc. (BNTC)vs ›

$307.13M

N/A

Artiva Biotherapeutics, Inc. (ARTV)vs ›

$346.15M

N/A

Enanta Pharmaceuticals, Inc. (ENTA)vs ›

$357.37M

N/A

46.02

35.66

31.75

BridgeBio Oncology Therapeutics Inc. (BBOT)vs ›

$292.79M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

CCCC Price/OCF Ratio Metrics

CCCC Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics